Anti-Integrin Therapy for IBD: Vedolizumab vs Natalizumab

Anti-integrin therapy for IBD is a class of biologic drugs that treats Crohn's disease and ulcerative colitis by blocking the traffic of inflammatory white blood cells into the intestinal wall. Two agents define this class. Vedolizumab, sold as Entyvio, is a gut-selective biologic that acts almost exclusively in the digestive tract. Natalizumab, sold as Tysabri, blocks a broader target and carries a serious brain-infection risk that shaped how it is used. Both are integrin receptor antagonists approved for moderately to severely active inflammatory bowel disease, or IBD, yet they differ sharply in selectivity, safety, route, and speed of effect. Understanding those differences helps explain why one has become a widely used first-choice biologic while the other is reserved for specific situations.

How Integrins Direct Immune Cells Into the Gut

Integrins are adhesion proteins on the surface of white blood cells that let those cells stick to blood vessel walls and cross into tissue. In IBD, memory T-lymphocytes destined for the gut display a specific integrin called alpha-4-beta-7. This integrin binds a partner molecule named mucosal addressin cell adhesion molecule-1, or MAdCAM-1, which is mainly expressed on gut endothelial cells. The pairing of alpha-4-beta-7 with MAdCAM-1 acts like a mailing address that routes immune cells specifically into the intestinal lining. When this trafficking runs unchecked, waves of lymphocytes accumulate in the bowel wall and drive the chronic inflammation of Crohn's disease and ulcerative colitis. Anti-integrin drugs interrupt this homing step rather than suppressing the immune system as a whole, which is the biological idea behind the alpha-4-beta-7 integrin IBD treatment approach.

How Vedolizumab Works: Gut-Selective Alpha-4-Beta-7 Blockade

Vedolizumab is a humanized monoclonal antibody that specifically binds the alpha-4-beta-7 integrin and blocks its interaction with MAdCAM-1, which stops memory T-lymphocytes from migrating across the vessel wall into inflamed gastrointestinal tissue. The defining feature of the Entyvio mechanism of action is what it leaves alone. According to the prescribing information, vedolizumab does not bind to or inhibit the alpha-4-beta-1 and alpha-E-beta-7 integrins and does not block the interaction of alpha-4 integrins with vascular cell adhesion molecule-1. Because alpha-4-beta-1 governs immune-cell traffic into other organs, including the brain, sparing it keeps the drug's action confined largely to the digestive tract. A pharmacology review describes how vedolizumab was engineered to reduce lymphocyte trafficking to the intestine by targeting the alpha-4-beta-7 heterodimer while leaving trafficking to the brain intact. That precision is what makes it a gut selective biologic.

How Natalizumab Works: Broader Alpha-4 Blockade

Natalizumab targets the alpha-4 subunit itself rather than a specific integrin pair. The Tysabri label states that natalizumab binds the alpha-4 subunit of both alpha-4-beta-1 and alpha-4-beta-7 integrins, which are expressed on the surface of nearly all white blood cells except neutrophils. By blocking alpha-4-beta-7, natalizumab reduces immune-cell entry into the gut in the same way vedolizumab does. By also blocking alpha-4-beta-1, it interferes with the binding of leukocytes to vascular cell adhesion molecule-1, an interaction that governs immune surveillance across many tissues, including the movement of lymphocytes across the blood-brain barrier. This wider reach explains both the drug's original approval for multiple sclerosis and the central safety problem that distinguishes natalizumab versus vedolizumab. Suppressing brain immune surveillance opens the door to a rare viral infection of the central nervous system.

The PML Risk That Separates the Two Drugs

The Tysabri label carries a boxed warning that natalizumab increases the risk of progressive multifocal leukoencephalopathy, or PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. PML is caused by reactivation of the JC virus, and the label identifies treatment duration, prior immunosuppressant use, and the presence of anti-JC virus antibodies as factors that raise the risk. Because of this danger, natalizumab is available only through a restricted distribution program called the TOUCH Prescribing Program, and dosing must be withheld at the first sign or symptom suggestive of PML. Vedolizumab's gut-selective design was intended to avoid exactly this problem. A mechanism review notes that, in contrast to natalizumab, vedolizumab does not interfere with lymphocyte trafficking to the brain, sidestepping the PML risk that constrained the earlier drug.

Route, Dosing, and Onset

Vedolizumab begins with intravenous induction. The label directs 300 mg infused at weeks 0, 2, and 6, then every eight weeks for intravenous maintenance. After the first two infusions, patients may switch to a 108 mg subcutaneous injection given once every two weeks using a prefilled syringe or the Entyvio Pen, which allows self-administration at home. Natalizumab is given only as 300 mg infused intravenously over about one hour every four weeks, always within the monitored TOUCH program. Onset is a practical difference. Vedolizumab can take longer to produce remission, and in the GEMINI 3 study of Crohn's patients who had failed prior therapy, induction of remission required about ten weeks of treatment rather than showing a clear early benefit at week six.

Vedolizumab Versus Natalizumab at a Glance

The table below summarizes the core mechanistic and practical distinctions between the two anti-integrin agents.

Feature	Vedolizumab (Entyvio)	Natalizumab (Tysabri)
Molecular target	Alpha-4-beta-7 integrin only	Alpha-4 subunit of alpha-4-beta-1 and alpha-4-beta-7
Selectivity	Gut-selective	Broad, including central nervous system
PML / JC virus risk	Not linked to brain trafficking	Boxed warning for PML
Distribution	Standard specialty pharmacy	Restricted TOUCH Program
Route	Intravenous, then optional subcutaneous	Intravenous only
Maintenance interval	Every 8 weeks IV or every 2 weeks subcutaneous	Every 4 weeks IV

These contrasts follow directly from mechanism. A narrower target produces a narrower footprint of both benefit and risk, which is why vedolizumab is often chosen when clinicians want to limit systemic immune effects.

Trial Evidence Behind Each Drug

Vedolizumab's approval rests on the GEMINI program. In GEMINI 1 for ulcerative colitis, week 6 response reached 47.1% with vedolizumab versus 25.5% with placebo, and week 52 remission favored the drug. In GEMINI 2 for Crohn's disease, week 6 remission was 14.5% versus 6.8% with placebo, with a larger separation during maintenance. GEMINI 3 focused on patients who had failed tumor necrosis factor antagonist therapy and showed benefit that emerged by week 10 rather than week 6. Natalizumab was studied earlier in the ENACT-1 and ENACT-2 trials and in the ENCORE trial, where week 8 response sustained through week 12 reached 48% versus 32% with placebo. A patient in the ENACT extension died of PML, which reshaped the drug's development.

Safety and Monitoring Differences

Gut selectivity gives vedolizumab a comparatively mild systemic-infection profile. The most common adverse reactions in trials were nasopharyngitis, headache, arthralgia, and nausea, and the label lists PML only as a theoretical precaution rather than an observed drug-caused event. Monitoring focuses on infusion or injection reactions, liver injury, and standard vaccination timing. Natalizumab demands a far heavier monitoring structure built around its brain-infection risk. Patients are typically tested for anti-JC virus antibodies to gauge PML risk, are watched for new neurological symptoms, and can receive the drug only through the TOUCH program described in its boxed warning. The trade-off is clear. Vedolizumab exchanges a slightly slower onset for a narrower and more predictable safety profile, while natalizumab offers a broad effect at the cost of intensive surveillance.

Anti-integrin therapy shows how a single design decision, choosing which integrin to block, cascades into differences in efficacy, safety, and daily use. Vedolizumab's tight focus on alpha-4-beta-7 keeps its action in the gut and avoids the JC virus complication that defined natalizumab, at the price of a slower path to remission and a need for patience during induction. Natalizumab's broader alpha-4 blockade remains a meaningful option for select patients with Crohn's disease, but only within a restricted program that reflects the seriousness of PML. For people weighing a gut-selective biologic, the two drugs illustrate that the target a medicine chooses, and the targets it deliberately spares, matter as much as whether it calms the bowel.